Publications scientifiques

2602 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2021

JOURNALClinical lymphoma, myeloma & leukemia

PREMIER AUTEURCampidelli A

TITREOn Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.

ANNÉE2021

JOURNALBMJ supportive & palliative care

PREMIER AUTEURLuporsi E

TITREIron deficiency in patients with cancer: a prospective cross-sectional study.

ANNÉE2021

JOURNALPharmaceuticals (Basel, Switzerland)

PREMIER AUTEURDardare J

TITREEpithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities.

ANNÉE2021

JOURNALVaccine

PREMIER AUTEURDalon F

TITREHuman papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study.

ANNÉE2021

JOURNALJournal of medical imaging and radiation oncology

PREMIER AUTEURLatge A

TITREImpact of pelvic dynamic acquisition on final reading of F-Fluorocholine positron emission tomography in patients with prostate adenocarcinoma: True need or unnecessary burden?

ANNÉE2021

JOURNALJournal of clinical medicine

PREMIER AUTEURMorizot R

TITREPatients with Persistent Polyclonal B-Cell Lymphocytosis Share the Symptomatic Criteria of Systemic Exertion Intolerance Disease.

ANNÉE2021

JOURNALCancers

PREMIER AUTEURBilla O

TITRERandomized Trial Assessing the Impact of Routine Assessment of Health-Related Quality of Life in Patients with Head and Neck Cancer.

ANNÉE2021

JOURNALCardiovascular and interventional radiology

PREMIER AUTEURCazzato RL

TITREAcute Bilateral Decrease in Vision Acuity Following Cryoablation of a Painful L5 Spinal Metastasis.

ANNÉE2021

JOURNALEMBO reports

PREMIER AUTEURBerico P

TITRECDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.

ANNÉE2021

JOURNALClinical lymphoma, myeloma & leukemia

PREMIER AUTEURCasasnovas RO

TITREComparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques